Form D · Other

Ventyx Biosciences, Inc.

San Diego, CA · CIK 0001851194

Offering snapshot reported Sep 30, 2024 · SEC filing

Reported sold
$27M
Offering amount: $27M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 23, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 30, 2024Initial$26,999,940No comparison1SEC filing
Sep 20, 2021Initial$50,999,991No comparisonNot reportedSEC filing
Jul 16, 2021Amendment$114,299,988$56,999,995vs Mar 15, 202124SEC filing
Mar 15, 2021Initial$57,299,993No comparison23SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-525420

Source: Form D, filed Sep 30, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Martin Auster Executive
Onaiza Cadoret Manier Director
Jigar Choksey Director
Mark S. Forman Executive
Richard Gaster Director
Sheila Gujrathi Director
Allison Hulme Director
Christopher W. Krueger Executive
Raju Mohan Director, Executive
Matthew Moore Executive
John Nuss Executive
Aaron Royston Director
Somasundaram Subramaniam Director
William White Director

Issuer details

Industry: Other (See others in industry)

Address:
12790 El Camino Real, Suite 200
San Diego, CA, 92130